<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="56965">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01832233</url>
  </required_header>
  <id_info>
    <org_study_id>REB12-73</org_study_id>
    <nct_id>NCT01832233</nct_id>
  </id_info>
  <brief_title>Prairie Renal Denervation Study</brief_title>
  <official_title>Prairie Renal Denervation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regina Qu'Appelle Health Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regina Qu'Appelle Health Region</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with hypertension are at a higher risk for cardiovascular disease and death so it is
      important to lower blood pressure to normal levels as quickly as possible. Previous research
      has established that renal nerve denervation successfully lowers blood pressure measured in
      the arm in the physician's office. This study is being conducted so that the investigators
      can determine whether renal nerve denervation also helps to lower blood pressure over 24
      hours, as well as central aortic blood pressure, which is pressure exerted by the aorta
      closer to the heart and may be a better predictor of cardiovascular problems. The
      investigators also want to know whether these beneficial effects on blood pressure can last
      up to 2 years, whether renal denervation reduces the number of medications patients need to
      take, and whether it reduces glucose and insulin levels in the blood since hypertension is
      also related to obesity and diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline in Peripheral Blood Pressure at 3 months Post-Renal Denervation</measure>
    <time_frame>Baseline to 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Peripheral Blood Pressure at 6 months Post-Renal Denervation</measure>
    <time_frame>Baseline to 6 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Peripheral Blood Pressure at 12-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 12 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Peripheral Blood Pressure at 18-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 18 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Peripheral Blood Pressure at 24-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 24 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Central Blood Pressure at 3-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Central Blood Pressure at 6-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 6 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Central Blood Pressure at 12-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 12 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Central Blood Pressure at 18-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 18 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Central Blood Pressure at 24-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 24 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in 24-Hour Ambulatory Blood Pressure at 3-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>For 24-hour blood pressure, we will record the following:
12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in 24-Hour Ambulatory Blood Pressure at 6-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 6 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>For 24-hour blood pressure, we will record the following:
12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in 24-Hour Ambulatory Blood Pressure at 12-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 12 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>For 24-hour blood pressure, we will record the following:
12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in 24-Hour Ambulatory Blood Pressure at 18-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 18 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>For 24-hour blood pressure, we will record the following:
12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in 24-Hour Ambulatory Blood Pressure at 24-months Post-Renal Denervation</measure>
    <time_frame>Baseline to 24 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>For 24-hour blood pressure, we will record the following:
12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in fasting glucose</measure>
    <time_frame>Baseline, Post 3, 6, 12, 18, 24 months after renal denervation treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>fasting blood measures of glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Cardiac Parameters</measure>
    <time_frame>Baseline, Post  12 and 24 months renal denervation treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using an echocardiogram, the following cardiac measures will be taken:
Left ventricle volume Left ventricle hypertrophy Left ventricle function Left atrial mass E-wave velocity E-prime velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in fasting insulin</measure>
    <time_frame>Baseline, Post 3, 6, 12, 18, 24 months after renal denervation treatment.</time_frame>
    <safety_issue>No</safety_issue>
    <description>fasting blood measure of insulin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Renal Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive renal denervation as a treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Symplicity Renal Denervation System</intervention_name>
    <description>Symplicity Renal Denervation System consists of two main components: the Symplicity Catheter; and the Symplicity Radio Frequency Generator.The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.</description>
    <arm_group_label>Renal Denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Glomerular filtration rate: 60-15 mls/min as per the modified diet in renal disease
             formula (Stage 3 and 4 Chronic Kidney Disease)

          -  Daytime systolic blood pressure on ambulatory monitor â‰¥ 135 mm Hg while taking 3 or
             more anti-hypertensives including a diuretic on maximal dose OR  ambulatory monitor
             systolic blood pressure is &lt;135 but taking 4 or more anti-hypertensives

          -  18 years and above

          -  A minimum of 20 mm of length and 4 mm of diameter for renal arteries on CT renal
             angiogram or formal renal angiogram

        Exclusion Criteria:

          -  not suitable for renal denervation based on the Indications for Use
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bhanu Prasad</last_name>
    <phone>306-352-3018</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Regina Qu'Appelle Health Region</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bhanu Prasad</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 11, 2013</lastchanged_date>
  <firstreceived_date>March 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
